
On July 4, President Donald Trump signed H.R. 1, the One Big Beautiful Bill Act, into law.
On Aug. 6, AMCP responded to FDA’s draft guidance on considerations in demonstrating biosimilar interchangeability with a biologic reference product. The draft guidance, issued on June 17, describes considerations regarding switching studies which demonstrate interchangeability between biosimilars and their reference biologic products.
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.